SouthState Corp’s Blueprint Medicines BPMC Stock Holding History

SouthState Corp’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5	Closed	-$443	–	1626
2025 Q1	$443	Buy	+5	New	+$488	﹤0.01%	1556

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SouthState Corp's BPMC Position: Q2 2025 in Review

SouthState Corp sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 5 shares — an estimated $443 sold.

SouthState Corp first reported a position in BPMC in Q1 2025 and held it in 1 quarter. The position peaked at $443 in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

SouthState Corp reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
SouthState Corp sold 5 Blueprint Medicines shares in Q2 2025, an estimated $443.
SouthState Corp first reported a position in Blueprint Medicines in Q1 2025 and held it in 1 quarter.
SouthState Corp's Blueprint Medicines position peaked at $443 in Q1 2025.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on SouthState Corp's 13F filing for Q2 2025, filed 6 Aug 2025.